However, because this protocol is more aggressive and less translatable to human conditions of NASH, statistically significant differences were achieved only for some of the investigated parameters (Suppl. Figure 1 A-E), including the decrease in IL-1β and CCL-2 transcript levels (Suppl. Fig. 1B), the decrease in collagen deposition (Suppl. Fig. 1C, D), TGF-β1 transcript levels (Suppl. Fig. 1E). The gene discussed is IL1B; the disease is metabolic dysfunction-associated steatohepatitis.